WTI crude surged 5% Tuesday on fresh Iran strikes near the Strait of Hormuz. OXY just posted record free cash…
Alnylam Is Worth Owning Before Friday’s S&P 500 Changes
Roughly $28 trillion tracks the S&P 500. The better question is whether Alnylam deserves a spot in your portfolio on…
CME Group Is the Stock to Own While the Fed Debate Rages
September hike odds rose from 35% to 58% in three sessions. CME's rates business earns on every tick of that…
AI Power Bottleneck: Not Chips, Castings
SpaceX’s blade foundry shows who controls AI build speed. Howmet fell about 7.5%.
Three Tools That Quietly Run Your Admin
A solopreneur survey claimed 22 hours a week lost to tasks that don't grow the business. Here is where to…
31 Days to a Funding Cliff
Two unreconciled CRs, one fiscal deadline, and a data blind spot that could leave the Fed guessing in October.
Five Days, One Decision: Trade Friday’s 8:30
Futures imply about a 58% September hike. Goldman still calls it unlikely, so this week’s data all rhymes.
AVGO Reports Wednesday. The $16B Line Is the Only One That Matters.
Broadcom's fiscal Q3 results land Sept. 2, with AI semiconductor revenue guidance at a make-or-break level.
Who Profits When Your Speaker Doubles in Price
The AI memory crunch is in the consumer aisle. The investor question is which of three companies has pricing power…
ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the…